Published: Jun, 2018
The pharmerging market is choc-o-bloc with vendors. This makes it both fragmented and cutthroat. The big names among them such as Merck & Co. Inc., F. Hoffmann-La Roche Ltd., Novartis AG, and Johnson & Johnson hold small amounts of share in the market on account of it. The new players, as of now, have found it difficult to gain a foothold for the very same reason.
To beat competition and surge ahead under such tough conditions, players in pharmerging market are seen pulling out all stops to expand into relatively untapped markets and grow their consumer base through product development.
A recent report by Transparency Market Research on the pharmerging market finds that it would rise at a healthy 11.3% CAGR over the course of the forecast period beginning from 2016 and ending in 2024. At this pace, the market which was worth US$552.80 mn in the year 2015 would likely attain a value of US$1.40 bn by 2024-end.
Product-wise, the pharmerging market is broadly classified into healthcare and pharmaceuticals. Of the two, the segment of pharmaceuticals accounts for a leading share because of the surging demand for both generic and branded drugs. Besides, emergence of various new and more effective therapies for treating a range of health conditions at affordable rates is also benefitting the market. Geographically, Asia Pacific has come to hold over half the market share and hence stands out among the rest of the regions. Going forward too, its market will likely retain sway over the rest because of swift pace of urbanization, increasing spends on medical research, and patent expirations. China is said to be mainly powering the region’s growth.
Increasing Occurrence of Non-communicable Diseases Majorly Boosts Market
The term pharmerging refers to developing nations where the usage of pharmaceuticals is growing by leaps and bounds. Their total spends on drugs has increased dramatically thus making them attractive targets for drug makers. Elaborates the lead analyst of the report, “The rising incomes, free trade agreements, improved life expectancies, large pool of elderly, and rising occurrence of non-communicable diseases are mainly serving to drive demand in pharmerging market. In addition, thrust on research and development is also having a positive impact.”
Popularity of Lower-cost Generics in Developing Nations Deals Blow to Growth
However, one factor posing a challenge to the market for pharmerging is the cost conscious nature of consumers in the emerging economies. As a result they mostly opt for lower-cost generics which makes it difficult for branded expensive products to gain traction. This is in turn is impacting negatively the overall revenue in the market.
Notwithstanding such setbacks, the market is predicted to rise owing to governments of various nations pouring in money to improve their healthcare sectors. Currently, cancer and autoimmune diseases alongside lifestyle diseases are generating maximum sales in the pharmerging market.
This review is based on the findings of a TMR report, titled, “Pharmerging Market (Product Type - Pharmaceuticals (Branded Prescription Drugs, Generic Drugs (Branded Generics, Unbranded Generics, and OTC Drugs) and Healthcare (Medical Devices, Diagnostic Instruments, and IT and Record Management); Economic Growth Levels - Tier - 1, Tier - 2, and Tier - 3; Indications - Lifestyle Diseases, Cancer and Autoimmune Diseases, and Infectious Diseases; Distribution Channel - Hospitals, Clinics, Retail Pharmacies, E-commerce, and Drug Stores) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017–2025.”
The report segments the Global Pharmerging Market into the following:
Global Pharmerging Market Segmentation, by Product
- Branded Prescription Drugs
- Generic Drugs
- Branded Generics
- Unbranded Generics
- OTC Drugs
- Medical Devices
- Diagnostic Instruments
- Others (IT and record management)
Global Pharmerging Market, by Indications
- Lifestyle Diseases
- Cancer and autoimmune diseases
- Infectious Diseases
Global Pharmerging Market, by Distribution Channel
- Retail Pharmacies
- Drug Stores
Global Pharmerging Market, by Region
- Asia Pacific
- Latin America
- Middle East and Africa
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.”
Transparency Market Research
90 State Street,
Albany NY - 12207
USA - Canada Toll Free: 866-552-3453